Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure - A report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD) -

Circulation Journal

Volumn 76, Issue 8, 2012, Pages 1920-1927

  Hamaguchi, Sanae ^a   Kinugawa, Shintaro ^a   Tsuchihashi Makaya, Miyuki ^a   Goto, Daisuke ^a   Yamada, Satoshi ^a   Yokoshiki, Hisashi ^a   Takeshita, Akira ^a   Tsutsui, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diuretics; Heart failure; Outcomes; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NITRATE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; WARFARIN;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; DEATH; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; TIME FACTORS;

EID: 84864378856     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1196     Document Type: Article

References (46)

1. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82.
2. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
3. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: Activation of the neurohumoral axis. Ann Intern Med 1985; 103: 1-6.
4. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311-1315.
5. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028-2035.
6. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301-1307.
7. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE trial. Eur J Heart Fail 2007; 9: 1064-1069.
8. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methods. Eur Heart J 2006; 27: 1431-1439.
9. Hamaguchi S, Kinugawa S, Goto D, Tsuchihashi-Makaya M, Yokota T, Yamada S, et al. Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure. Circ J 2011; 75: 2403-2410.
10. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 2006; 70: 1617-1623.
11. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Ide T, Takeshita A, et al. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1442-1447.
12. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Takeshita A, Yokoshiki H, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1901-1908.
13. Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi-Makaya M, Yokota T, Takeshita A, et al. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 2084-2090.
14. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
15. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J 2010; 160: 1156-1162.
16. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Yokota T, Goto K, et al. Body mass index is an independent predictor of long-term outcomes in patients hospitalized with heart failure in Japan. Circ J 2010; 74: 2605-2611.
17. Tsuchihashi-Makaya M, Furumoto T, Kinugawa S, Hamaguchi S, Goto K, Goto D, et al. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Hypertens Res 2010; 33: 197-202.
18. Tsuchihashi-Makaya M, Kinugawa S, Yokoshiki H, Hamaguchi S, Yokota T, Goto D, et al. Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. Circ J 2010; 74: 1364-1371.
19. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, et al. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 2011; 151: 143-147.
20. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Goto K, Goto D, Furumoto T, et al. Sex differences with respect to clinical characteristics, treatment, and long-term outcomes in patients with heart failure. Int J Cardiol 2011; 150: 338-339.
21. Rosenbaum PR. Sensitivity to hidden bias. In: Rosenbaum PR, editor. Observational studies. 2nd edn. New York: Springer; 2002; 110-124.
22. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759-1764.
23. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.
24. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
25. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729.
26. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
27. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32: 865-879.
28. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007; 75: 29-39.
29. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 121: 1645-1654.
30. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study. Circulation 2004; 110: 3667-3673.
31. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: Evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004; 15: 2195-2203.
32. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009.
33. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678.
34. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996.
35. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113: 2713-2723.
36. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail 2007; 13: 422-430.
37. Komukai K, Ogawa T, Yagi H, Date T, Sakamoto H, Kanzaki Y, et al. Decreased renal function as an independent predictor of re-hospitalization for congestive heart failure. Circ J 2008; 72: 1152-1157.
38. Shiba N, Matsuki M, Takahashi J, Tada T, Watanabe J, Shimokawa H. Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Circ J 2008; 72: 173-178.
39. Vaz Perez A, Otawa K, Zimmermann AV, Stockburger M, Muller-Werdan U, Werdan K, et al. The impact of impaired renal function on mortality in patients with acutely decompensated chronic heart failure. Eur J Heart Fail 2010; 12: 122-128.
40. Robertson JI. Diuretics, potassium depletion and the risk of arrhythmias. Eur Heart J 1984; 5(Suppl A): 25-28.
41. Hollifield JW. Potassium and magnesium abnormalities: Diuretics and arrhythmias in hypertension. Am J Med 1984; 77: 28-32.
42. Dyckner T. Relation of cardiovascular disease to potassium and magnesium deficiencies. Am J Cardiol 1990; 65: 44K-46K.
43. Dyckner T, Wester PO. Potassium/magnesium depletion in patients with cardiovascular disease. Am J Med 1987; 82: 11-17.
44. Kjeldsen K. Hypokalemia and sudden cardiac death. Exp Clin Cardiol 2010; 15: e96-e99.
45. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
46. America HFSO. Disease management in heart failure. J Card Fail 2006; 12: e58-e69.